Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study

Research output: Contribution to journalArticlepeer-review

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{1a967dbc1e7449a9866003d5e6d5026c,
title = "Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study",
abstract = "Rheumatoid arthritis (RA) is associated with increased morbidity and mortality from cardiovascular disease (CVD). This can be only partially attributed to traditional CVD risk factors such as dyslipidaemia and their downstream effects on endothelial function. The most common lipid abnormality in RA is reduced levels of high-density lipoprotein (HDL) cholesterol, probably due to active inflammation. In this longitudinal study we hypothesised that anti-tumor necrosis factor-α (anti-TNFα) therapy in patients with active RA improves HDL cholesterol, microvascular and macrovascular endothelial function.",
author = "Aamer Sandoo and {Veldhuijzen van Zanten}, {Jet J C S} and Toms, {Tracey E} and Douglas Carroll and Kitas, {George D}",
year = "2012",
doi = "10.1186/1471-2474-13-127",
language = "English",
volume = "13",
pages = "127",
journal = "BMC Musculoskeletal Disorders",
issn = "1471-2474",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis

T2 - a pilot study

AU - Sandoo, Aamer

AU - Veldhuijzen van Zanten, Jet J C S

AU - Toms, Tracey E

AU - Carroll, Douglas

AU - Kitas, George D

PY - 2012

Y1 - 2012

N2 - Rheumatoid arthritis (RA) is associated with increased morbidity and mortality from cardiovascular disease (CVD). This can be only partially attributed to traditional CVD risk factors such as dyslipidaemia and their downstream effects on endothelial function. The most common lipid abnormality in RA is reduced levels of high-density lipoprotein (HDL) cholesterol, probably due to active inflammation. In this longitudinal study we hypothesised that anti-tumor necrosis factor-α (anti-TNFα) therapy in patients with active RA improves HDL cholesterol, microvascular and macrovascular endothelial function.

AB - Rheumatoid arthritis (RA) is associated with increased morbidity and mortality from cardiovascular disease (CVD). This can be only partially attributed to traditional CVD risk factors such as dyslipidaemia and their downstream effects on endothelial function. The most common lipid abnormality in RA is reduced levels of high-density lipoprotein (HDL) cholesterol, probably due to active inflammation. In this longitudinal study we hypothesised that anti-tumor necrosis factor-α (anti-TNFα) therapy in patients with active RA improves HDL cholesterol, microvascular and macrovascular endothelial function.

U2 - 10.1186/1471-2474-13-127

DO - 10.1186/1471-2474-13-127

M3 - Article

C2 - 22824166

VL - 13

SP - 127

JO - BMC Musculoskeletal Disorders

JF - BMC Musculoskeletal Disorders

SN - 1471-2474

ER -